Literature DB >> 18269332

Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges.

Alfonso Mele1, Maria Elena Tosti, Andrea Mariano, Renato Pizzuti, Antonio Ferro, Bianca Borrini, Carla Zotti, Pierluigi Lopalco, Filippo Curtale, Emanuela Balocchini, Enea Spada.   

Abstract

BACKGROUND: Italy had intermediate-level endemicity for hepatitis B virus (HBV) infection in the 1970s and 1980s. In 1991, vaccination of infants and adolescents became mandatory. We report the impact of universal vaccination 14 years after its beginning.
METHODS: We performed a case-control study within a population-based surveillance for acute viral hepatitis. The incidence of acute hepatitis B (AHB) was estimated for the time since 1991, and the association between AHB and the considered risk factors was analyzed for the period 2001-2005.
RESULTS: The incidence of AHB progressively decreased from 1991 to 2005, mainly for persons in the age groups targeted by the universal vaccination campaign: there was a 24-fold and 50-fold decrease in the 15-24-year and 0-14-year age groups, respectively; for the > or =25-year age group, the incidence halved. Owing to the persons' ages, approximately 3% of total AHB cases should have been the target of vaccination campaign. In 2004-2005, foreigners accounted for 14% of total cases and for 57% of persons who should have been targets for vaccination. Missed opportunities for immunization were documented for approximately 50% of patients with AHB who reported cohabitation with HBV carriers and for 70% of those who reported injection drug use. The strongest associations with AHB were found for blood transfusion (adjusted odds ratio [OR(adj)], 8.4; 95% confidence interval [CI], 2.7-26), cohabitation with HBV carriers (OR(adj), 5.3; 95% CI, 3.6-7.7), injection drug use (OR(adj), 3.8; 95% CI, 2.5-5.8), and unsafe sexual practices (OR(adj), 2.8; 95% CI, 1.9-4.2).
CONCLUSION: Universal vaccination has contributed to a decreasing AHB incidence in Italy, especially by reducing the risk of infection among persons aged 15-24 years. Most infections occur in persons aged > or =25 years in association with injection drug use, unsafe sexual activity, percutaneous treatment, and iatrogenic exposure. Improvement of vaccine coverage in high-risk groups and adherence to infection control measures during surgery and percutaneous treatment are needed. The high risk still associated with blood transfusion needs to be further investigated, with consideration of occult HBV infection in blood donors. The potential spread of HBV infection from the immigrant population deserves adequate health policy prevention programs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269332     DOI: 10.1086/528687

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Presence of anti-HBs antibodies in blood donors 18-22 years after vaccination and implications for the selection of candidates for plasmapheresis for the production of hyperimmune plasma.

Authors:  Massimo De Paschale; Stefania Latella; Arianna Gatti; Bruno Brando; M Teresa Manco; Luisa Belvisi; Debora Cagnin; Teresa Cerulli; Alessia Paganini; Maurizio Macchi; Pierangelo Clerici
Journal:  Blood Transfus       Date:  2015-10-29       Impact factor: 3.443

2.  Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group.

Authors:  Claudio Velati; Laura Fomiatti; Lorella Baruffi; Vanessa Piccinini; Daniele Prati; Anna Reina; Andrea Lobbiani; Alessandro Zanetti; Luisa Romanò
Journal:  Blood Transfus       Date:  2011-07-21       Impact factor: 3.443

Review 3.  Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow.

Authors:  Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

4.  Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood.

Authors:  Mohammad Qawasmi; Monjed Samuh; Dieter Glebe; Wolfram H Gerlich; Maysa Azzeh
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Serological pattern of Hepatitis B, C, and HIV infections among immigrants in Sicily: epidemiological aspects and implication on public health.

Authors:  Fabio Tramuto; Walter Mazzucco; Carmelo Massimo Maida; Andrea Affronti; Mario Affronti; Giuseppe Montalto; Francesco Vitale
Journal:  J Community Health       Date:  2012-06

Review 6.  Unsolved problems and future perspectives of hepatitis B virus vaccination.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

7.  Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study.

Authors:  L Bracciale; M Fabbiani; A Sansoni; L Luzzi; L Bernini; G Zanelli
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

8.  Sero-epidemiology of hepatitis B markers in the population of Tuscany, Central Italy, 20 years after the implementation of universal vaccination.

Authors:  Sara Boccalini; Elettra Pellegrino; Emila Tiscione; Giovanna Pesavento; Angela Bechini; Miriam Levi; Stefano Rapi; Stefano Mercurio; Francesco Mannelli; Marta Peruzzi; Cesare Berardi; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-25       Impact factor: 3.452

Review 9.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Lack of implementation of Hepatitis B Virus (HBV) vaccination policy in household contacts of HBV carriers in Italy.

Authors:  Paola Scognamiglio; Enrico Girardi; Mario Fusco; Pierluca Piselli; Silvana Russo Spena; Carmela Maione; Francesco Aurelio Pisanti; Diego Serraino
Journal:  BMC Infect Dis       Date:  2009-06-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.